Affitech appoints cfo
Stig Jarle Pettersen was formerly a consultant to the Danish antibody medicines firm
Pettersen will be a member of the executive management of Affitech with managing director Martin Welschof and chief scientific officer Alexander Duncan.
Pettersen is a Norwegian state authorised public accountant with more than 20 years of experience at Hafslund Nycomed, Helicopter Services Group, Alpharma, Actavis and most recently as chief financial officer at Xellia Pharmaceuticals.
Pettersen worked as a consultant for Affitech in September 2009 and participated in the process of restructuring and refinancing the company. He now joins the company when, due to investment by TransNova in April, it is able to finance the further development of its two leading drug candidates in collaboration with NTSPlus of Russia.
Affitech expects to file a Clinical Trial Application in 2011 for its anti-VEGF antibody AT001/r84, whose main indication is for anti-angiogenesis treatment in several cancers.
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration]()
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration
Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
